在PTCy时代年轻无关供者可能优于HLA匹配:来自EBMT的ALWP研究
该回顾性研究分析了1011例首次或第二次完全缓解的急性髓系白血病患者,接受基于移植后环磷酰胺的无关供者造血干细胞移植。供者年龄超过30岁对复发、无白血病生存、总生存和无GVHD无复发生存有负面影响;CMV阴性供者用于CMV阴性受者与改善无白血病生存相关。
要点
- 供者年龄超过30岁与较差的复发、无白血病生存、总生存和无GVHD无复发生存相关。
- CMV阴性供者用于CMV阴性受者与改善的无白血病生存相关。
- 9/10错配无关供者和女性供者用于男性受者未显著影响移植结局。
核心结论
- 对于接受基于PTCy的无关供者造血干细胞移植的急性髓系白血病患者,供者年龄小于30岁显著改善生存。
- 在此背景下,供者年龄可能应优先于HLA匹配考虑。
- 此外,CMV阴性供者对于CMV阴性受者更可取。
- 然而,需要进一步研究来验证和完善这些建议。
研究设计与样本
- 该研究为回顾性分析,纳入1011例首次或第二次完全缓解的急性髓系白血病患者,接受基于移植后环磷酰胺的无关供者造血干细胞移植。
- 供者中位年龄29岁(范围18-64),621例(61%)为10/10匹配无关供者。
- 主要终点为无白血病生存。
主要发现
- 供者年龄超过30岁对复发有负面影响(HR 1.38;95% CI 1.06-1.8)。
- 供者年龄超过30岁对无白血病生存有负面影响(HR 1.4;95% CI 1.12-1.74)。
- 供者年龄超过30岁对总生存有负面影响(HR 1.45;95% CI 1.14-1.85)。
- 供者年龄超过30岁对无GVHD无复发生存有负面影响(HR 1.29;95% CI 1.07-1.56)。
- CMV阴性供者用于CMV阴性受者与改善的无白血病生存相关(HR 0.74;95% CI 0.55-0.99)。
关键数值与推荐
- 供者年龄超过30岁:复发HR 1.38(95% CI 1.06-1.8),无白血病生存HR 1.4(95% CI 1.12-1.74),总生存HR 1.45(95% CI 1.14-1.85),无GVHD无复发生存HR 1.29(95% CI 1.07-1.56)。
- CMV阴性供者用于CMV阴性受者:无白血病生存HR 0.74(95% CI 0.55-0.99)。
- 9/10错配无关供者和女性供者用于男性受者未显著影响任何移植结局。
临床怎么用
- 对于接受基于PTCy的无关供者造血干细胞移植的急性髓系白血病患者,供者年龄小于30岁显著改善生存。
- 在此背景下,供者年龄可能应优先于HLA匹配考虑。
- CMV阴性供者对于CMV阴性受者更可取。
- 需要进一步研究来验证和完善这些建议。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
There is a paucity of information on how to select the most appropriate unrelated donor (UD) in hematopoietic stem cell transplantation (HSCT) using posttransplant cyclophosphamide (PTCy). We retrospectively analyzed the characteristics of 10/10 matched UDs (MUDs) and 9/10 mismatched UDs (MMUDs) that may affect transplant outcomes in patients with acute myeloid leukemia (AML) in first or second complete remission (CR1 or CR2). The primary end point was leukemia-free survival (LFS). Overall, 1011 patients were included with a median age of 54 years (range, 18-77). Donors had a median age of 29 years (range, 18-64); 304 (30%) were females, of which 150 (15% of the whole group) were donors to male recipients, and 621 (61%) were MUDs; 522 (52%) had negative cytomegalovirus (CMV-neg) serostatus, of which 189 (19%) were used for CMV-neg recipients. Donor age older than 30 years had a negative impact on relapse (hazard ratio [HR], 1.38; 95% confidence interval [CI], 1.06-1.8), LFS (HR, 1.4; 95% CI, 1.12-1.74), overall survival (HR 1.45; 95% CI, 1.14-1.85) and graft-versus-host disease (GVHD) free, relapse-free survival (HR, 1.29; 95% CI, 1.07-1.56). In addition, CMV-neg donors for CMV-neg recipients were associated with improved LFS (HR, 0.74; 95% CI, 0.55-0.99). The use of MMUD and female donors for male recipients did not significantly impact any transplant outcomes. For patients undergoing HSCT from a UD with PTCy for AML, donor age <30 years significantly improves survival. In this context, donor age might be prioritized over HLA match considerations. In addition, CMV-neg donors are preferable for CMV-neg recipients. However, further research is needed to validate and refine these recommendations.
引用
- Sanz J, Labopin M, Choi G, et al. Younger unrelated donors may be preferable over HLA match in the PTCy era: a study from the ALWP of the EBMT. Blood. 2024. PMID: 38657278. doi:10.1182/blood.2023023697
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。